US20190194333A1 - Klrg1 depletion therapy - Google Patents

Klrg1 depletion therapy Download PDF

Info

Publication number
US20190194333A1
US20190194333A1 US16/327,576 US201716327576A US2019194333A1 US 20190194333 A1 US20190194333 A1 US 20190194333A1 US 201716327576 A US201716327576 A US 201716327576A US 2019194333 A1 US2019194333 A1 US 2019194333A1
Authority
US
United States
Prior art keywords
klrg1
antibody
cells
cell
depleting agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US16/327,576
Other languages
English (en)
Inventor
Steven Greenberg
Stefano Vincenzo Gulla
Kenneth Evan Thompson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brigham and Womens Hospital Inc
Childrens Medical Center Corp
Original Assignee
Brigham and Womens Hospital Inc
Childrens Medical Center Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham and Womens Hospital Inc, Childrens Medical Center Corp filed Critical Brigham and Womens Hospital Inc
Priority to US16/327,576 priority Critical patent/US20190194333A1/en
Publication of US20190194333A1 publication Critical patent/US20190194333A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Definitions

  • the present invention generally relates to KLRG1-expressing-cell depletion therapies and therapeutics.
  • the present invention more specifically relates to KLRG1-expressing-cell depletion therapies and therapeutics for autoimmune disease, transplant rejection, hematologic malignancies, and solid tumors.
  • cytotoxic T cells are a key element in the destruction of muscle that occurs in the disease inclusion body myositis (Arahata and Engel, 1984, Arahata and Engel, 1986, Arahata and Engel, 1988, Amemiya et al., 2000).
  • autoimmune diseases such as multiple sclerosis (Zang et al., 2004, Friese and Fugger, 2009), rheumatoid arthritis (Carvalheiro et al., 2014), psoriasis (Hijnen et al., 2013), inflammatory bowel disease (Muller et al., 1998, Bisping et al., 2001), autoimmune thyroid disease (Okajima et al., 2009), type 1 diabetes (Faustman and Davis, 2009), alopecia areata (Xing et al., 2014), Bechet's disease (Yu et al., 2004), ankylosing spondylitis (Schirmer et al., 2002, Trevino et al., 2004), and primary biliary cirrhosis (Kita, 2007).
  • T cell large granular lymphocytic leukemia is a leukemia characterized by expansion of late-stage differentiated CD8+ T cells
  • NK cell lymphoproliferative disorder is a leukemia characrerized by NK cell expansion (Lamy and Loughran, 2011).
  • Extranasal NK/T cell lymphoma is a related disorder (Takata et al., 2015).
  • Inclusion body myositis may overlap substantially with T cell large granular lymphocytic leukemia (T-LGLL).
  • T-LGLL T cell large granular lymphocytic leukemia
  • Numerous cell surface molecules expressed by cytotoxic T cells have been identified.
  • therapeutic developments based upon targeting these molecules are limited and there remains a need for new therapeutics utilizing these targets for various indications including autoimmune disease, transplant rejection, hematologic malignancies, and solid tumors.
  • the invention is based, at least in part, on the discovery that killer cell lectin-like receptor G1 (KLRG1), a cell surface marker known to be present on senescent cytotoxic T cells, is also present on cytotoxic T cells with high-killing potential.
  • KLRG1 killer cell lectin-like receptor G1
  • cytotoxic T cells with high-killing potential.
  • KLRG1 marks T cells that are directly killing healthy muscle cells.
  • KLRG1-expressing T cells can be pathogenic and are therefore an advantageous target for cell depletion therapy.
  • administering to a subject in need thereof an effective amount of KLRG1 depleting agent e.g., a KLRG1-expressing-cell depleting agent
  • an effective amount of KLRG1 depleting agent e.g., a KLRG1-expressing-cell depleting agent
  • ADCC antibody dependent cellular cytotoxicity
  • the invention has numerous therapeutic uses.
  • the invention can be used for treating inclusion body myositis (IBM). More generally, the invention can be used for treating, including in some cases preventing, various diseases associated with KLRG1-expressing cells (i.e., by depleting the KLRG1-expressing cells).
  • Embodiments of the invention include treating, and in some cases preventing, autoimmune diseases, transplant rejection, hematologic malignancies, and solid tumors.
  • Advantages of the invention include the ability to preferentially target CD8+ cytotoxic T and/or NK cells for depletion and potentially greater efficacy and reduced side effects.
  • the population of KLRG1-expressing immune cells more abundantly express cytotoxic molecules than the population of total CD2+ or CD3+ expressing T cells, and are more specific to cytotoxic T cells than CD52+ hence potential for greater efficacy.
  • KLRG1 is a marker that increases with antigen experience, predicting more specific antigen directed immune responses and, hence potential for greater efficacy and reduced side effects.
  • the invention provides a method of treating a subject comprising administering to a subject in need thereof an effective amount of a killer cell lectin-like receptor G1 (KLRG1) depleting agent (a KLRG1-expressing-cell depleting agent), thereby depleting CD8+ cytotoxic T and/or NK cells in vivo.
  • KLRG1 depleting agent can specifically target and deplete CD8+ cytotoxic T and/or NK cells expressing KLRG1.
  • the invention provides a method of treating a subject comprising administering to a subject in need thereof an effective amount of a killer cell lectin-like receptor G1 (KLRG1) depleting agent (a KLRG1-expressing-cell depleting agent) with effector killing function.
  • KLRG1 depleting agent can specifically target and deplete pathogenic, or otherwise harmful or undesired, cells expressing KLRG1.
  • the invention uses a killer cell lectin-like receptor G1 (KLRG1) depleting agent (a KLRG1-expressing-cell depleting agent).
  • KLRG1 killer cell lectin-like receptor G1
  • the invention uses an mRNA or cDNA encoding the depleting agent.
  • the invention uses a pharmaceutical composition comprising an effective amount of the depleting agent.
  • the depleting agent is an antibody or antigen binding fragment thereof, or antibody mimetic.
  • the antibody is monoclonal.
  • the antibody or antigen binding fragment thereof, or antibody mimetic comprises a human or humanized antibody.
  • the antibody or antigen binding fragment thereof, or antibody mimetic comprises: a. a full length antibody Fab antibody that binds KLRG1 with effector function antibody dependent cell-mediated cytotoxicity (ADCC); b. an antibody that binds KLRG1 with effector function complement dependent cytotoxicity (CDC); c. an antibody that binds KLRG1 with effector function antibody-drug conjugate (ADC); d. an Fc-cadherin fusion protein; e. a fusion protein E-cadherin/Fc; f. a fusion protein R-cadherin/Fc; g. a fusion protein N-cadherin/Fc; h. a chimeric antigen receptor; or i. a multispecific antibody.
  • ADCC effector function antibody dependent cell-mediated cytotoxicity
  • CDC effector function complement dependent cytotoxicity
  • ADC effector function antibody-drug conjugate
  • d. an Fc-cadherin fusion protein e.
  • the chimeric antigen receptor and wherein the chimeric antigen receptor comprises a specificity portion of a KLRG1 antibody grafted onto a T cell.
  • the multispecific antibody comprises a bispecific or trispecific antibody.
  • the depleting agent binds KLRG1.
  • the KLRG1 is the extracellular domain of human KLRG1.
  • the depleting agent cross reacts with the extracellular domains of human and cynomolgus KLRG1.
  • the depleting agent binds to an epitope of the extracellular domain of KLRG1, wherein the epitope is at least 90% identical in human and cynomolgus.
  • the depleting agent binds to KLRG1 and is not clone 13F12F2, 14C2A07, REA261, 13A2, SA231A2, 2F1, 13A2, or REA261.
  • the invention uses a killer cell lectin-like receptor G1 (KLRG1) depleting agent, other than any of the agents described in PCT Application No. PCT/US17/35621.
  • KLRG1 killer cell lectin-like receptor G1
  • the depleting agent binds to KLRG1 and is not a mouse antibody.
  • the depleting agent binds KLRG1, thereby labeling CD8+ cytotoxic T and/or NK cells for depletion.
  • the depleting agent binds KLRG1, thereby inducing Antibody-Dependent Cellular Cytotoxicity (ADCC) or Complement Dependent Cytotoxicity (CDC).
  • ADCC Antibody-Dependent Cellular Cytotoxicity
  • CDC Complement Dependent Cytotoxicity
  • the depleting agent selectively targets and depletes T and/or NK cells expressing KLRG1.
  • the depleting agent is administered by providing an mRNA encoding the depleting agent to the subject.
  • the subject has an autoimmune disease.
  • the autoimmune disease is rheumatoid arthritis, psoriasis, inclusion body myositis (IBM), multiple sclerosis, ulcerative colitis, lymphocytic colitis, idiopathic thrombocytopenic purpura, primary biliary cholangitis, or type 1 diabetes.
  • IBM inclusion body myositis
  • multiple sclerosis ulcerative colitis
  • lymphocytic colitis idiopathic thrombocytopenic purpura
  • primary biliary cholangitis or type 1 diabetes.
  • the subject has or is at risk of developing transplant rejection.
  • the transplant rejection is kidney rejection, preferably T cell mediated kidney rejection after transplantation.
  • the subject has a hematologic malignancy.
  • the hematologic malignancy is a leukemia.
  • the leukemia is T cell leukemia, NK cell leukemia, large granular lymphocytic leukemia (LGLL), or chronic lymphocytic leukemia (CLL).
  • LLL large granular lymphocytic leukemia
  • CLL chronic lymphocytic leukemia
  • the subject has a lymphoma.
  • the lymphoma is T cell lymphoma, preferably anaplastic large cell lymphoma.
  • the subject has a solid tumor.
  • the solid tumor is a breast cancer, gastric cancer, ovarian cancer, prostate cancer, glioma, glioblastoma, melanoma, lung cancer, kidney cancer, or tongue cancer.
  • the lung cancer can be, for example, non-small cell lung cancer.
  • the kidney cancer can be, for example, renal cell carcinoma.
  • the method of treatment further comprises administering to the subject an effective amount of a checkpoint modulator therapy.
  • the KLRG1 depleting agent and checkpoint modulator therapies are synergistic.
  • the checkpoint modulator therapy comprises an anti-PD-1, anti-PD-L1, or anti-CTLA-4 therapy.
  • the subject has failed or has not responded to a prior cancer therapy.
  • the invention uses the KLRG1 depleting agent in the preparation of medicament for treatment or prevention of an autoimmune disease, a transplant rejection, a hematologic malignancy, or a solid tumor.
  • FIG. 1 shows that human KLRG1 is expressed on greater proportions of cytotoxic T and NK cells than helper T cells.
  • FIGS. 2A and 2B show a progression of increasing expression of KLRG1 on T cells with increased differentiation.
  • FIG. 3 shows increased KLRG1 gene expression in IBM muscle compared to normal muscle. Twelve IBM muscle biopsies compared with 5 normal muscle biopsies.
  • FIG. 4 shows expression of KLRG1 by immunohistochemistry on muscle-invading T cells in inclusion body myositis (4 patient samples shown).
  • FIG. 5 shows expression of KLRG1 in lymph node, demonstrating the vast majority of CD8+ T cells in lymph node do not express KLRG1.
  • FIGS. 6A and 6B show sera response of immunized mice to KLRG1.
  • FIG. 7 shows binding of antibodies derived from hybridoma clones to human KLRG1 extracellular domain.
  • FIGS. 8A-8C show KLRG1+ T cells in blood are increased in abundance in patients with IBM compared to age-matched healthy individuals.
  • FIGS. 9A and 9B show expression of KLRG1 on CD8+CD57+ blood T cells in a patient with inclusion body myositis and large granular lymphocytic leukemia.
  • FIGS. 10A and 10B show expression of KLRG1 by immunohistochemistry on tissue-invading leukemic cells in large granular lymphocytic leukemia (LGLL) and chronic lymphocytic leukemia (CLL), respectively.
  • LGLL large granular lymphocytic leukemia
  • CLL chronic lymphocytic leukemia
  • FIG. 11 shows that KLRG1 is slightly overexpressed in intestinal biopsies from patients with ulcerative colitis.
  • FIG. 12 shows that KLRG1 is overexpressed in patients with idiopathic thrombocytopenic purpura.
  • FIG. 13 shows that KLRG1 is overexpressed in colon biopsies from patients with lymphocytic colitis.
  • FIG. 14 shows that KLRG1 is overexpressed in kidney biopsies from patients with T cell mediated kidney rejection after transplantation.
  • FIG. 15 shows that KLRG1 is overexpressed in lymph node from patients with anaplastic large cell lymphoma compared with normal CD4+ T cells.
  • FIG. 16 shows that KLRG1 is overexpressed in synovial biopsies from patients with rheumatoid arthritis.
  • FIG. 17 shows that KLRG1 is overexpressed in skin biopsies from patients with psoriasis.
  • FIG. 18 shows that KLRG1 is overexpressed in liver biopsies from patients with primary biliary cholangitis.
  • FIG. 19 shows that KLRG1 is overexpressed in pancreas tissue from patients with type 1 diabetes.
  • FIG. 20 shows that KLRG1 is overexpressed in blood from patients with T-cell large granular lymphocytic leukemia.
  • FIG. 21 shows that KLRG1 is expressed by T cells in T cell leukemias and lymphomas.
  • FIG. 22 shows that KLRG1 is slightly overexpressed in brain from patients with multiple sclerosis.
  • FIG. 23 shows widespread infiltration of many tumor types by KLRG1-expressing T cells.
  • FIGS. 24A-24C show KLRG1+ cells infiltrating melanoma tumors in 3 patients.
  • FIG. 24D shows no KLRG1+ cells in normal skin.
  • FIG. 25 shows KLRG1+ cells infiltrating renal cell carcinoma tumors in 4 patients.
  • FIG. 26 shows KLRG1+ cells infiltrating non-small cell lung cancer tumors in 4 patients.
  • FIGS. 27A-27C show depletion of CD8+CD57+ terminally differentiated cells using a KLGR1 depleting agent.
  • FIG. 28 shows that KLRG1 is overexpressed in tongue biopsies from patients with tongue carcinoma.
  • SEQ ID NO:1 is the sequence of human KLRG1 extra cellular domain (ECD) isotype 1.
  • SEQ ID NO:2 is the sequence of human KLRG1 ECD isotype 2.
  • SEQ ID NO:3 is the sequence of cynomolgus KLRG1 ECD.
  • the invention is based, at least in part, on the discovery that KLRG1, a cell surface marker known to be present on senescent cytotoxic T cells, is also present on cytotoxic T cells with high-killing potential.
  • KLRG1 marks T cells that are directly killing human muscle cells.
  • KLRG1-expressing T cells in certain samples are pathogenic and are therefore a favorable target for depletion therapy.
  • KLRG1 killer cell lectin-like receptor G1
  • ADCC antibody dependent cellular cytotoxicity
  • the invention has numerous therapeutic uses, particularly in diseases where a subset of pathogenic cells overexpressing KLRG1, e.g., 1.2-fold, 1.3-fold, 1.4-fold, 1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold, 10-fold, 20-fold, 30-fold, 40-fold, 50-fold, 60-fold, 70-fold, 80-fold, 90-fold, 100-fold and/or higher, relative to healthy subjects.
  • the subset of pathogenic cells may be, for example, CD8+ cytotoxic T cells or NK cells.
  • the invention can be used for treating inclusion body myositis. More generally, the invention can be used for treating, and in some cases preventing, autoimmune disease, transplant rejection, hematologic malignancies, and solid tumors.
  • Advantages of the invention include the ability to preferentially target CD8+ cytotoxic T and/or NK cells for depletion. Advantages of the invention also include greater efficacy and reduced side effects. For example, the population of KLRG1-expressing immune cells more abundantly express cytotoxic molecules than the population of total CD2+ or CD3+ expressing T cells, and are more specific to cytotoxic T cells than CD52 hence potential for greater efficacy; and KLRG1 is a marker that increases with antigen experience, predicting more specific antigen directed immune responses and, hence potential for greater efficacy and reduced side effects.
  • the invention provides a method of treating a subject comprising administering to a subject in need thereof an effective amount of a killer cell lectin-like receptor G1 (KLRG1) depleting agent, thereby depleting CD8+ cytotoxic T and/or NK cells in vivo.
  • KLRG1 killer cell lectin-like receptor G1
  • the treatment can be for an autoimmune disease, transplant rejection, hematologic malignancies, and solid tumors (examples discussed below).
  • the invention also provides a method of treating a subject comprising administering to a subject in need thereof an effective amount of a killer cell lectin-like receptor G1 (KLRG1) depleting agent with effector killing function.
  • KLRG1 killer cell lectin-like receptor G1
  • the treatment can be for an autoimmune disease, transplant rejection, hematologic malignancies, and solid tumors (examples discussed below).
  • the invention uses a killer cell lectin-like receptor G1 (KLRG1) depleting agent.
  • KLRG1 killer cell lectin-like receptor G1
  • the invention uses an mRNA or cDNA encoding the depleting agent.
  • the invention uses a pharmaceutical composition comprising an effective amount of the depleting agent.
  • KLRG1 KLRG1 and its ligands
  • depleting agents pharmaceutical compositions, treatment and administration, and illustrative examples are discussed, in turn, below.
  • KLRG1 Killer Cell Lectin-Like Receptor G1 (KLRG1) and its Ligands
  • Killer cell lectin-like receptor G1 (KLRG1) is type II transmembrane protein and is a co-inhibitory receptor modulating the activity of T and NK cells. Its extracellular portion contains a C-type lectin domain whose known ligands are cadherins and its intracellular portion contains an immunoreceptor tyrosine-based inhibitory motif (ITIM) domain responsible for co-inhibition of T cell receptor (TCR) mediated signaling (Tessmer et al., 2007).
  • the ligand can be E-cadherin, N-cadherin, R-cadherin, or a combination thereof.
  • KLRG1 distribution and function differ in the rodent compared to the human. Originally identified on a rodent mast cell line (Guthmann et al., 1995), KLRG1 is not expressed on human mast cells, basophils, monocytes, or neutrophils (Voehringer et al., 2002). Human KLRG1 is a more potent co-inhibitory receptor than mouse KLRG1. KLRG1-mediated inhibition under physiological conditions is only observed with human lymphocytes because KLRG1 dimers have greater potency than monomers, and human KLRG1 forms exclusively dimers while mouse KLRG1 exists as monomers and dimers (Hofmann et al., 2012).
  • KLRG1 expression in humans is limited to T and NK cells. It is expressed on greater proportions of cytotoxic T and NK cells than helper T cells ( FIG. 1 , KLRG1 expression of lymphocyte subsets, human blood flow cytometry). Specifically, FIG. 1 shows the greater expression of KLRG1 on cytotoxic CD8+ T cells and NK cells than on CD4+ helper T cells. Within the CD8+ cytotoxic T cell population, increased KLRG1 expression correlates with increased antigen specific potency, as shown in FIGS. 2A and 2B . Specifically, FIGS. 2A and 2B show increasing expression of KLRG1 on T cells with increased differentiation. FIG.
  • FIG. 2A cytotoxicity and cytokines of CD8+ T cell subsets, human blood gene expression shows that cytotoxic potential of T cells increases from TN ⁇ TCM ⁇ TEM ⁇ TEMRA.
  • FIG. 2B % KLRG1+CD6+ T cells of human blood CD8+ subpopulation by flow cytometry shows that KLRG1 expression increases from TN ⁇ TCM ⁇ TEM ⁇ TEMRA.
  • CD8+ cytotoxic T cells differentiate in response to antigen, from na ⁇ ve T cells to central memory, effector memory, and effector memory RA cells, they express increased amounts of KLRG1.
  • KLRG1 marks cells with high capacity for cytotoxic killing. This cytotoxicity may be undesired (in the case of autoimmune disease and transplant rejection) or desired (in the case of cancer or chronic infectious disease).
  • KLRG1 function in humans is substantially different than KLRG1 function in mice
  • mouse data is of limited applicability to the treatment of human disease.
  • KLRG1 translational data in human diseases There are no published studies of KLRG1 expression by immunohistochemistry in any human diseased or healthy tissue sample.
  • KLRG1 is a marker of immunosenescence (Akbar and Henson, 2011, Apetoh et al., 2015).
  • KLRG1 is human or cynomolgus KLRG1, preferably human KLRG1, including any functional part thereof.
  • KLRG1 can be Human-KLRG1-ECD-Isotype 1 (SEQ ID NO:1), including any functional part thereof.
  • KLRG1 is Human-KLRG1-ECD-Isotype2 (SEQ ID NO:2), including any functional part thereof.
  • KLRG1 is Cynomolgus-KLRG1 (SEQ ID NO: 3), including any functional part thereof.
  • the invention provides a method of treating a subject comprising administering to a subject in need thereof an effective amount of a killer cell lectin-like receptor G1 (KLRG1) depleting agent.
  • KLRG1 killer cell lectin-like receptor G1
  • the term “depleting agent” is an agent that substantially reduces the number of a specific cell population.
  • the cell population targeted by the depleting agent is identified by at least one characteristic feature, for example a cell surface marker (e.g., the presence and/or overexpression of KLRG1 relative to other cells).
  • the agent reduces the number of KLRG1-expressing and/or overexpressing cells (e.g., the KLRG1 depleting agent does not deplete KLRG1 in isolation, but rather depletes cells characterized by KLRG1).
  • the depleting agent used in the methods of the invention is capable of reducing the number of the targeted cell population by 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 99%, and/or 100% relative to untreated target cells or target cells treated with IgG1 isotype antibody.
  • the depleting agent used in the methods of the invention is an antibody or antigen binding fragment thereof, or antibody mimetic with effector function antibody dependent cell-mediated cytotoxicity (ADCC), effector function complement dependent cytotoxicity (CDC); effector function antibody-drug conjugate (ADC); a fusion protein that binds specifically to the targeted cell type (e.g., a ligand of a receptor specific to the targeted cell type) and effects cell killing via conjugation to a drug or an immunoglobulin with effector ADCC or CDC function; or a small molecule agent that specifically targets (e.g., binds) and depletes a cell type (e.g., by inducing cell death or destruction, for example via toxin delivery or metabolic alterations).
  • ADCC effector function antibody dependent cell-mediated cytotoxicity
  • CDC effector function complement dependent cytotoxicity
  • ADC effector function antibody-drug conjugate
  • a fusion protein that binds specifically to the targeted cell type e.g., a ligand
  • the depleting agent is an antibody or antigen binding fragment thereof, or antibody mimetic.
  • antibody is used in the broadest sense and covers, for example, single anti-KLRG1 monoclonal antibodies.
  • monoclonal antibody refers to an antibody obtained from a population of substantially homogeneous antibodies, e.g., the individual antibodies comprising the population are identical except for possible naturally-occurring mutations that may be present in minor amounts.
  • An antibody can be monoclonal.
  • An antibody can be a human or humanized antibody.
  • Antibody fragments can include a portion of an intact antibody, preferably the antigen binding or variable region of the intact antibody.
  • antibody fragments include Fab, Fab′, F(ab′)2, and Fv fragments; diabodies; linear antibodies; single-chain antibody molecules; and multispecific antibodies formed from antibody fragments.
  • “Fv” includes the minimum antibody fragment which contains a complete antigen-recognition and binding site. This region consists of a dimer of one heavy- and one light-chain variable domain in tight, non-covalent association. It is in this configuration that the three CDRs of each variable domain interact to define an antigen-binding site on the surface of the VH-VL dimer. Collectively, the six CDRs confer antigen-binding specificity to the antibody. However, even a single variable domain (or half of an Fv comprising only three CDRs specific for an antigen) has the ability to recognize and bind antigen, although at a lower affinity than the entire binding site.
  • the Fab fragment also contains the constant domain of the light chain and the first constant domain (C H 1) of the heavy chain.
  • Fab fragments differ from Fab′ fragments by the addition of a few residues at the carboxy terminus of the heavy chain C H 1 domain including one or more cysteines from the antibody hinge region.
  • Fab′-SH is the designation herein for Fab′ in which the cysteine residue(s) of the constant domains bear a free thiol group.
  • F(ab′) 2 antibody fragments originally were produced as pairs of Fab′ fragments which have hinge cysteines between them. Other chemical couplings of antibody fragments are also known.
  • immunoglobulins can be assigned to different classes. There are five major classes of immunoglobulins: IgA, IgD, IgE, IgG, and IgM, and several of these may be further divided into subclasses (isotypes), e.g., IgG1, IgG2, IgG3, IgG4, IgA, and IgA2.
  • Single-chain Fv” or “sFv” antibody fragments comprise the V H and V L domains of antibody, wherein these domains are present in a single polypeptide chain.
  • the Fv polypeptide further comprises a polypeptide linker between the V H and V L domains which enables the sFv to form the desired structure for antigen binding.
  • the antibody or antigen binding fragment thereof, or antibody mimetic comprises a human or humanized antibody.
  • Humanized forms of non-human (e.g., murine) antibodies are chimeric immunoglobulins, immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab′, F(ab′) 2 or other antigen-binding subsequences of antibodies) which contain minimal sequence derived from non-human immunoglobulin.
  • Humanized antibodies include human immunoglobulins (recipient antibody) in which residues from a complementary determining region (CDR) of the recipient are replaced by residues from a CDR of a non-human species (donor antibody) such as mouse, rat or rabbit having the desired specificity, affinity and capacity.
  • CDR complementary determining region
  • Fv framework residues of the human immunoglobulin are replaced by corresponding non-human residues.
  • Humanized antibodies may also comprise residues which are found neither in the recipient antibody nor in the imported CDR or framework sequences.
  • the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the FR regions are those of a human immunoglobulin consensus sequence. Methods for humanizing non-human antibodies are well known in the art.
  • the depleting agents may also be affinity matured, for example using selection and/or mutagenesis methods known in the art.
  • an “affinity matured” antibody is one with one or more alterations in one or more hyper variable regions thereof which result in an improvement in the affinity of the antibody for antigen, compared to a parent antibody which does not possess those alteration(s).
  • an affinity matured antibody has nanomolar or even picomolar affinities for the target antigen.
  • Preferred affinity matured antibodies have an affinity which is five times, more preferably 10 times, even more preferably 20 or 30 times greater than the starting antibody (generally murine, humanized or human) from which the matured antibody is prepared.
  • a KLRG1 depleting agent includes functional equivalents to an anti-KLRG1 antibody according to the invention.
  • a KLRG1 depleting agent can be a binding agent that binds to or specifically binds to KLRG1 (e.g., human KLRG1), for example native KLRG1 on a cell surface.
  • KLRG1 binding agent may be cross reactive with various similar KLRG1 proteins (e.g., with highest affinity for one, such as human KLRG1, and lower affinity for others, such as mouse KLRG1).
  • the depleting agent is a blocking or antagonist binding agent.
  • “Blocking” or “antagonist” means the agent (e.g., antibody or binding fragment/mimic thereof) is one which inhibits or reduces biological activity of the antigen it binds.
  • Certain blocking agents or antagonist agents substantially or completely inhibit the biological activity of the antigen.
  • a KLRG1 binding agent can block KLRG1 signaling (e.g., thereby disrupting KLRG1 signaling and activating CD8+ cytotoxic T and/or NK cells).
  • the antibody or antigen binding fragment thereof, or antibody mimetic comprises: a. a full length antibody Fab antibody that binds KLRG1 with effector function antibody dependent cell-mediated cytotoxicity (ADCC); b. an antibody that binds KLRG1 with effector function complement dependent cytotoxicity (CDC); c. an antibody that binds KLRG1 with effector function antibody-drug conjugate (ADC); d. an Fc-cadherin fusion protein; e. a fusion protein E-cadherin/Fc; f. a fusion protein R-cadherin/Fc; g. a fusion protein N-cadherin/Fc; h. a chimeric antigen receptor; or i. a multispecific antibody.
  • ADCC effector function antibody dependent cell-mediated cytotoxicity
  • CDC effector function complement dependent cytotoxicity
  • ADC effector function antibody-drug conjugate
  • d. an Fc-cadherin fusion protein e.
  • the chimeric antigen receptor comprises a specificity portion of a KLRG1 antibody grafted onto a T cell.
  • the multispecific antibody comprises a bispecific or trispecific antibody.
  • the depleting agent binds KLRG1.
  • the KLRG1 is the extracellular domain of human KLRG1.
  • the depleting agent cross reacts with the extracellular domains of human and cynomolgus KLRG1.
  • the depleting agent binds to an epitope of the extracellular domain of KLRG1, wherein the epitope is at least 90% identical in human and cynomolgus.
  • the depleting agent binds to KLRG1 and is not a mouse antibody.
  • the depleting agent binds KLRG1, thereby labeling CD8+ cytotoxic T and/or NK cells for depletion.
  • the depleting agent binds KLRG1, thereby inducing Antibody-Dependent Cellular Cytotoxicity (ADCC) or Complement Dependent Cytotoxicity (CDC).
  • ADCC Antibody-Dependent Cellular Cytotoxicity
  • CDC Complement Dependent Cytotoxicity
  • the depleting agent selectively targets and depletes T and/or NK cells expressing KLRG1.
  • the depleting agent is new and not previously known antibody.
  • Known anti-KLRG1 antibodies include clone 13F12F2 (eBioscience), which is a mouse anti-human KLRG1 antibody that binds to the extracellular domain and has demonstrated reactivity against human cells in flow cytometry, clones 14C2A07 (Biolegend) and SA231A2 (Biolegend), which are reported to be anti-human KLRG1 antibodies, clone 13A2 (EBioscience) which is said to bind a similar epitope to clone 13F12F2, clone REA261 (Miltenyi Biotec) which also reportedly binds human KLRG1, and clone 2F1, which is a hamster anti-mouse KLRG1 antibody that some vendors (e.g., Biolegend) report to be reactive against human while others (e.g., Abcam) report reactivity to only mouse.
  • some vendors e.g., Biolegend
  • the KLRG1 antagonist comprises a binding agent that binds to KLRG1 and that is not clone 13F12F2, 14C2A07, SA231A2, or 2F1.
  • the KLRG1 depleting agent can be administered by providing an mRNA encoding the depleting agent to the subject.
  • mRNA approaches are being developed by Moderna Therapeutics, CureVac, and the like.
  • the KLRG1 depleting agent (a KLRG1-expressing-cell depleting agent) is prepared as a pharmaceutical composition, for example as a pharmaceutical composition for use as a medicament.
  • the pharmaceutical composition is for use as a medicament for an autoimmune disease (e.g., rheumatoid arthritis, psoriasis, inclusion body myositis (IBM), multiple sclerosis, ulcerative colitis, lymphocytic colitis, idiopathic thrombocytopenic purpura, or type 1 diabetes); transplant rejection (e.g., kidney rejection, preferably T cell mediated kidney rejection after transplantation); a hematologic malignancy (e.g., a leukemia such as T cell leukemia, NK cell leukemia, large granular lymphocytic leukemia (LGLL), or chronic lymphocytic leukemia (CLL) or a lymphoma such as T cell lymphoma, preferably anaplastic large cell
  • autoimmune disease e
  • KLRG1 depleting agent as a pharmaceutical composition according to known methods.
  • compositions can include a carrier.
  • Carriers as used herein can include pharmaceutically acceptable carriers, excipients, or stabilizers that are nontoxic (or relatively non-toxic) to the cell or subject being exposed thereto at the dosages and concentrations employed.
  • the physiologically acceptable carrier is an aqueous pH buffered solution.
  • physiologically acceptable carriers include buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid; low molecular weight (less than about 10 residues) polypeptide; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, arginine or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrins; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; salt-forming counterions such as sodium; and/or nonionic surfactants such as TWEENTM, polyethylene glycol (PEG), and PLURONICSTM.
  • buffers such as phosphate, citrate, and other organic acids
  • antioxidants including ascorbic acid
  • proteins such as serum albumin,
  • the KLRG1 depleting agent is comprised in an injectable formulation, for example, a subcutaneous, intravenous, intramuscular, intrathecal or intraperitoneal injection formulation.
  • injectable formulations can be aqueous solutions, for example in physiologically compatible buffers such as Hanks' solution, Ringer's solution, or physiological saline buffer.
  • the injectable formulation can contain formulatory agents such as suspending, stabilizing and/or dispersing agents.
  • the KLRG1 depleting agent can be in a dried or powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.
  • the KLRG1 depleting agent is not any of the KLRG1/ligand binding agents disclosed in PCT Application No. PCT/US17/35621.
  • the invention provides methods comprising administering the KLRG1 depleting agent (a KLRG1-expressing-cell depleting agent) according to any of the aspects or embodiments disclosed herein, or the pharmaceutical composition according to any of the aspects or embodiments disclosed herein, to a subject in need thereof.
  • the subject is a human.
  • methods according to the invention are carried out in vivo (e.g., as opposed to ex vivo).
  • treatment can refer to both therapeutic treatment and prophylactic or preventative measures, wherein the object is to prevent or slow down (lessen) the targeted pathologic condition or disorder.
  • Those in need of treatment can include those already with the disorder, those prone to have the disorder, or those in whom the disorder is to be prevented.
  • the invention provides methods for treating a condition associated with overexpression KLRG-1.
  • the invention targets a subset of cells, for example T cells and/or NK cells that express higher than normal levels of KLRG-1.
  • the invention provides methods for treating an autoimmune disease.
  • the autoimmune disease can be, for example, rheumatoid arthritis, psoriasis, inclusion body myositis (IBM), multiple sclerosis, ulcerative colitis, lymphocytic colitis, idiopathic thrombocytopenic purpura, primary biliary cholangitis, or type 1 diabetes.
  • IBM inclusion body myositis
  • multiple sclerosis ulcerative colitis
  • lymphocytic colitis idiopathic thrombocytopenic purpura
  • primary biliary cholangitis or type 1 diabetes.
  • cytotoxic T cells are implicated in the pathogenesis of these diseases. In accordance with the present invention, depletion of such cytotoxic T cells provides a therapeutic benefit.
  • the invention provides methods for treating or preventing transplant rejection.
  • the transplant rejection can be, for example, kidney rejection (e.g., T cell mediated kidney rejection after transplantation).
  • the invention provides methods for treating a hematologic malignancy.
  • the hematologic malignancy can be, for example, a leukemia such as T cell leukemia, NK cell leukemia, large granular lymphocytic leukemia (LGLL), or chronic lymphocytic leukemia (CLL).
  • the hematologic malignancy can be, for example, a lymphoma such as T cell lymphoma, anaplastic large cell lymphoma (ALCL), peripheral T cell lymphoma (PTCL), or angioimmunoblastic T cell lymphoma (AITCL).
  • KLRG1 is expressed by T cells in these leukemias and lymphomas to a similar extent by gene expression as normal or activated T cells, the majority of which express KLRG1.
  • depletion of such cytotoxic T cells provides a therapeutic benefit.
  • the invention provides methods for treating a solid tumor.
  • the solid tumor can be, for example, a breast cancer, gastric cancer, ovarian cancer, prostate cancer, glioma, glioblastoma, melanoma, or lung cancer.
  • KLRG1 is a co-inhibitory receptor present on T and NK cells, and engagement by its ligands results in T and NK cell inhibition. These inhibited T and NK cells furthermore appear to inhibit the function of other T and NK cells (without wishing to be bound by any particular theory, possibly through space occupying or other cell-cell interactions).
  • KLRG1-expressing T cells to its ligand, E-cadherin, expressed on a cancer cell surface
  • E-cadherin expressed on a cancer cell surface
  • non-KLRG1-expressing T cells can obstruct non-KLRG1-expressing T cells from reaching the cancer cell surface and killing the cancer cell.
  • Removal of such inhibited KLRG1-expressing-cells e.g., ineffective T and/or NK cells
  • E-cadherin expression on human breast carcinoma cells affects trastuzumab-mediated ADCC through KLRG1 on NK cells (Yamauchi et al., 2011)
  • administering can include contacting an exogenous pharmaceutical, therapeutic agent, diagnostic agent, or composition to the animal, human, subject, cell, tissue, organ, or biological fluid.
  • administering and “treatment” include in vivo, as well as in some embodiments, in vitro or ex vivo treatments. In various embodiments, the methods are carried out in vivo.
  • Treat” or “treating” means to administer a therapeutic agent, such as a composition containing any of the depleting agents of the present invention, internally or externally to a subject or patient having one or more disease symptoms, or being suspected of having a disease, for which the agent has therapeutic activity.
  • the agent is administered in an amount effective to alleviate one or more disease symptoms in the treated subject or population, whether by inducing the regression of or inhibiting the progression of such symptom(s) by any clinically measurable degree.
  • the amount of a therapeutic agent that is effective to alleviate any particular disease symptom may vary according to factors such as the disease state, age, and weight of the patient, and the ability of the drug to elicit a desired response in the subject. Whether a disease symptom has been alleviated can be assessed by any clinical measurement typically used by physicians or other skilled healthcare providers to assess the severity or progression status of that symptom.
  • the term “effective amount” is a concentration or amount of the KLRG1 depleting agent which results in achieving a particular stated purpose.
  • An “effective amount” of a KLRG1 depleting agent can be determined empirically.
  • a “therapeutically effective amount” is a concentration or amount of a KLRG1 depleting agent which is effective for achieving a stated therapeutic effect. This amount can also be determined empirically.
  • the KLRG1 depleting agent can be administered by providing an mRNA encoding the depleting agent to the subject.
  • the treatment can prolong the subject's survival. In various embodiments, the treatment can prevent or reduce the progression of the cancer and/or metastasis.
  • Antibodies binding KLRG1 were generated by immunization of mice with purified recombinant protein antigens: Human-KLRG1 ECD Isotype 1 (SEQ ID NO: 1), Human-KLRG1 ECD Isotype 2 (SEQ ID NO:2) and Cytomolgus-KLRG1 ECD (SEQ ID NO:3).
  • Balb/c and SJL mice were immunized every 2 weeks with recombinant KLRG1 protein and sera collected for testing after the second and fourth immunization.
  • FIG. 6A show a specific serum response to the cynomolgus KLRG1 in the immunized mice.
  • FIG. 6B show a specific serum response to the human KLRG1 in the immunized mice.
  • Anti-KLRG1 antibody activity was measured by ELISA. The response was shown to be mediated by production of antibodies in the mouse recognizing human and cynomolgus KLRG1.
  • FIG. 7 shows a dose-dependent binding curve of 9 hybridoma clones isolated from immunized mice.
  • ELISA was performed by first immobilizing human KLRG1 (SEQ ID NO:2) on immunosorbent 96-well plates, followed by exposure to a dose-dependent titration of antibodies. Bound antibodies were visualized by anti-mouse-HRP conjugated detection.
  • FIG. 7 shows that splenocytes isolated from the spleens of immunized mice are able to produce antibodies that recognize KLRG1.
  • Example 2 Gene Expression of KLRG1 is Higher Among CD8+ and NK Cells than CD4+ T Cells, and KLRG1 Expression Correlates with CD8+ T Cell Cytotoxic Potential
  • Cytotoxic cells consist of CD8+ T cells and NK cells. Analysis via abstraction from published figures of flow cytometry data from healthy donors in publications with PubMed ID#s (PMID) of Ser. No. 12/393,723, 20394788, 23966413, 26583066, and 27566818 demonstrates the greater percentage of KLRG1+ cells amongst CD8+(relative-fold 2.5) T cells and CD56+NK cells (relative-fold 2.4) compared to CD4+T helper cells (relative-fold 1.0) ( FIG. 1 ).
  • CD8+ cytotoxic T cells differentiate from na ⁇ ve cells to increasingly potent effector cells, characterized by central memory (TCM), effector memory (TEM) and effector (TEMRA) cells.
  • TCM central memory
  • TEM effector memory
  • TEMRA effector
  • the cytotoxic potential of CD8+ T cells within these differentiation subsets is highly correlated with proportions of KLRG1+ cells within these subsets by flow cytometry ( FIGS. 2A and 2B ).
  • FIGS. 2A and 2B Gene expression analysis in FIG. 2A was performed on microarray data available in dataset E-TABM-40 of the Array Express database of the European Bioinformatics Institute. Flow cytometry data in FIG.
  • FIG. 3 shows analysis of microarray data from the Gene Expression Omnibus (GEO) dataset GSE39454. Increased expression of KLRG1 is observed in IBM muscle compared to normal muscle.
  • GEO Gene Expression Omnibus
  • FIG. 4 shows immunohistochemical staining of muscle biopsy sample from 20 patients with IBM. Representative immunohistochemical staining images from four patients are shown in FIG. 4 , which shows KLRG1+ infiltrating cells (stained black) attacking muscle fibers in all patients. Isotype controls were used as negative controls (not shown).
  • FIG. 5 shows limited expression of KLRG1 on CD8+ T cells (stained black) in lymph node, indicating predicted relative sparing of protective memory T cells after KLRG1-expressing cell depletion. Representative staining images are shown of two human lymph node samples. Isotype controls were used as negative controls (not shown).
  • FIGS. 8A and 8B show representative example flow cytometry results of IBM patient ( FIG. 8A ) and healthy donor ( FIG. 8B ). Increased numbers of CD8+ KLRG1+ T cells were observed in IBM patients ( FIG. 8A ) compared to healthy donors ( FIG. 8B ). Mean age for each group was 65.
  • FIG. 8C shows average % total blood lymphocytes of IBM patients and healthy donors.
  • FIGS. 9A and 9B show, by flow cytometry, a proportion of CD8+CD57+ leukemic cells (shown as P2 in FIG. 9A ) express KLRG1 ( FIG. 9B , cells gated from FIG. 9A as indicated) in a patient with IBM and T cell large granular lymphocytic leukemia (T-LGLL).
  • FIGS. 10A and O1B show KLRG1+ infiltrating cells (stained black) attacking muscle by immunohistochemistry in a patient with IBM and T-LGLL and in a patient with IBM and chronic lymphocytic leukemia, respectively. Isotype controls were used as negative controls (not shown).
  • FIG. 11 shows analysis of expression data (E-GEOD-59071) from intestinal biopsies from 74 patients with active ulcerative colitis compared to 5 patients with normal intestine. Increased expression of KLRG1 is observed in intestinal biopsies from patients with active ulcerative colitis compared to patients with normal intestine (1.27 fold ratio). Dataset obtained from ArrayExpress database at the European Bioinformatics Institute and analyzed for KLRG1 expression. Accordingly, ulcerative colitis is an attractive target for therapies according to the present invention.
  • Antibodies that bind to the extracellular portion of KLRG1 can be produced by several techniques including but not limited to: mouse hybridoma technology, phage display, yeast display, retrocyte display, humanized mouse technology, ribosome display. Other and additional methods are known in the art and may be developed in connection with the application of the present invention.
  • mouse hybridoma technology can be used to generate antibodies that bind to KLRG1 and deplete KLRG1-expressing cells.
  • Strains of mice commonly used for antibody generation can be used, for example, Balb/c or SJL strains. Multiple mice can be injected repeatedly at 2 weeks intervals with antigen to produce an immune response.
  • Several forms of the antigen can be injected either alone or in combination and with the addition of adjuvants such as KLH (keyhole limpet hemocyanin) known to enhance the immune response of the host to foreign antigens.
  • Antigens can be in the form of purified recombinant KLRG1, cDNA coding for KLRG1, cells expressing KLRG1 on their surface or peptides derived from the sequence of KLRG1.
  • the immune response against KLRG1 can be monitored by ELISA titer.
  • the ELISA can be carried out by first immobilizing recombinant KLRG1 on suitable ELISA microtiter plates. After 12 hour incubation, the plates can be washed with phosphate saline and blocked with 1% solution of BSA in phosphate buffered saline. Sera derived from immunized mice can be serially diluted in phosphate buffered saline and allowed to interact with the surface bound antigen in the microtiter plates. Excess sera can be washed away and the amount of binding can be visualized using standard techniques such as addition of anti-mouse antibody conjugated to HRP.
  • mice can be boosted with antigen until a sufficiently high level of signal can be detected in their serum at which point the spleen can be removed from the mice.
  • Splenocytes derived from immunized mice can be fused with myeloma derived (SP2/0) using standard protocols in use in the field.
  • the resulting hybridoma cells can express and secrete antibodies that can be tested for binding to recombinant KLRG1 using ELISA and to cell expressed KLRG1 using FACS.
  • Hybridoma cell lines that produce antibodies with desired binding characteristics can be sub-cloned and the variable regions of the antibody sequenced. Recombinant antibodies using these variable mouse regions and human constant regions can produced by standard techniques, and can be evaluated in functional assays. (e.g., for binding and/or depleting activity).
  • FIGS. 27A-C show flow cytometry of human whole blood collected in heparin comparing baseline to 2.5 hours of incubation with IgG1 isotype antibody (Iso), anti-KLRG1 mouse/human IgG1 chimeric antibody CHI101(101), anti-KLRG1 mouse/human IgG1 chimeric antibody CHI104 (104), and anti-CD2 antibody siplizumab (Sip), a known potent T cell depleting antibody used as a positive control.
  • Antibody CHI101 and CHI104 resulted in selective depletion of CD8+CD57+ T cells and CD8+CD57+NK cells.
  • FIG. 28 shows analysis of expression data (GSE34115) from tongue biopsies from 90 patients with tongue carcinoma compared to 31 patients without tongue carcinoma. Increased expression of KLRG1 (2.16-fold ratio) was observed in tongue biopsies from patients with tongue carcinoma. Dataset was obtained from ArrayExpress database at the European Bioinformatics Institute and analyzed for KLRG1 expression. Accordingly, tongue carcinoma is an attractive target for therapies according to the present invention.
  • Example 8 Idiopathic Thrombocytopenic Purpura
  • FIG. 12 shows analysis of blood CD3+ T cell expression data (GSE574) from 2 patients with ITP compared to 2 healthy persons. Increased expression of KLRG1 (2.69-fold ratio) was observed in CD3+ T cells of patients with ITP. Dataset was obtained from Gene Expression Omnibus database at the National Center for Bioinformatics and analyzed for KLRG1 expression. Accordingly, idiopathic thrombocytopenic purpura is a particularly attractive target for therapies according to the present invention.
  • FIG. 13 shows analysis of expression data (GSE65107) from colon biopsies of 4 patients with lymphocytic colitis compared to colon biopsies of 4 healthy persons. Increased expression of KLRG1 (3.8-fold ratio) was observed in colon biopsies of patients with lymphocytic colitis. Dataset was obtained from Gene Expression Omnibus database at the National Center for Bioinformatics and analyzed for KLRG1 expression. Accordingly, lymphocytic colitis is a particularly attractive target for therapies according to the present invention.
  • FIG. 14 shows analysis of expression data (GSE36059) from patients with renal transplant rejection compared to nephrectomies. Increased expression of KLRG1 (2.69-fold ratio) was observed in renal transplantation rejection kidney biopsies. Dataset obtained from Gene Expression Omnibus database at the National Center for Bioinformatics and analyzed for KLRG1 expression, with additional analysis through NextBio. Accordingly, renal transplant rejection is a particularly attractive target for therapies according to the present invention.
  • FIG. 15 shows analysis of expression data (GSE6338) from lymph node biopsies from 6 patients with anaplastic large cell lymphoma compared to normal CD4+ T cells from lymph node in 5 patients. Increased expression of KLRG1 (3.55-fold ratio) was observed in lymphnode biopsies from patients with anaplastic large cell lymphoma. Dataset obtained from Gene Expression Omnibus database at the National Center for Bioinformatics and analyzed for KLRG1 expression. Accordingly, anaplastic large cell lymphoma is a particularly attractive target for therapies according to the present invention.
  • FIG. 16 shows analysis of expression data (GSE1919) from synovium biopsies from patients with rheumatoid arthritis compared to normal subjects. Increased expression of KLRG1 (3.55-fold ratio) was observed in synovium biopsies from patients with rheumatoid arthritis. Dataset obtained from Gene Expression Omnibus database at the National Center for Bioinformatics and analyzed for KLRG1 expression. Accordingly, rheumatoid arthritis is a particularly attractive target for therapies according to the present invention.
  • FIG. 17 shows analysis of expression data (GSE52471) from skin biopsies from patients with psoriasis compared to normal subjects. Increased expression of KLRG1 (1.14-fold ratio) was observed in skin biopsies from patients with psoriasis. Dataset obtained from Gene Expression Omnibus database at the National Center for Bioinformatics and analyzed for KLRG1 expression. Accordingly, psoriasis is a particularly attractive target for therapies according to the present invention.
  • FIG. 18 shows analysis of expression data (GSE79850) from liver biopsies from patients with primary biliary cholangitis eventually requiring liver transplantation compared to normal subjects. Increased expression of KLRG1 (6.03-fold ratio) was observed in liver biopsies from patients with primary biliary cholangitis. Dataset obtained from Gene Expression Omnibus database at the National Center for Bioinformatics and analyzed for KLRG1 expression. Accordingly, primary biliary cholangitis is a particularly attractive target for therapies according to the present invention.
  • FIG. 19 shows analysis of expression data (GSE72492) from pancreas from patients with type 1 diabetes compared to normal subjects. Increased expression of KLRG1 (1.66-fold ratio) was observed in pancreas from patients with type 1 diabetes. Dataset obtained from Gene Expression Omnibus database at the National Center for Bioinformatics and analyzed for KLRG1 expression. Accordingly, type 1 diabetes is a particularly attractive target for therapies according to the present invention.
  • FIG. 20 shows analysis of expression data (GSE10631) from blood from patients with T cell large granular lymphocytic leukemia compared to normal subjects. Similar or increased expression of KLRG1 (1.39-fold ratio) was observed in blood from patients with T cell large granular lymphocytic leukemia. Dataset obtained from Gene Expression Omnibus database at the National Center for Bioinformatics and analyzed for KLRG1 expression. Accordingly, these T cell large granular lymphocytic leukemia samples contain KLRG1 and T cell large granular lympchocytic leukemia is a particularly attractive target for therapies according to the present invention.
  • FIG. 21 shows analysis of expression data (GSE19069) from lymphoma biopsies from patients with a variety of T cell leukemias and lymphomas, including anaplastic large cell lymphoma (ALCL), angioimmunoblastic T-cell lymphoma (AITCL), and peripheral T-cell lymphoma (PTCL). Similar expression of KLRG1 was observed in the various T cell lymphomas compared to normal T cells (range 0.45- to 1.52-fold increase). Dataset obtained from Gene Expression Omnibus database at the National Center for Bioinformatics and analyzed for KLRG1 expression. Accordingly, these T cell lymphomas contain KLRG1-expressing T cells and are particularly attractive targets for therapies according to the present invention.
  • ACL anaplastic large cell lymphoma
  • AITCL angioimmunoblastic T-cell lymphoma
  • PTCL peripheral T-cell lymphoma
  • FIG. 22 shows analysis of expression data (GSE5839) from brain biopsies from patients with a multiple sclerosis and compared to normal brain. Elevated expression of KLRG1 is observed compared to control brain (1.23-fold). Dataset obtained from Gene Expression Omnibus database at the National Center for Bioinformatics and analyzed for KLRG1 expression. Accordingly, multiple sclerosis is a particularly attractive target for therapies according to the present invention.
  • FIG. 23 shows KLRG1 is expressed by tumor infiltrating lymphocytes in a wide variety of cancer, as detected by RNAseq expression.
  • TCGA raw RNAseq data was downloaded from the TCGA database.
  • X-axis denotes log 2 RPKM values, Y-axis contains cancer types, each dot represents the level of KLRG1 expression in a single cancer tissue sample.
  • FIG. 23 shows expression of KLRG1 in tumor samples in many cancer types. Cancer types listed from left to right are: uveal melanoma, uterine carcinoma, uterine carcinosarcoma, thyroid carcinoma, thymoma, testicular germ cell tumor, melanoma, sarcoma, rectal adenocarcinoma, prostate cancer, pheochromocytoma, pancreatic adenocarcinoma, ovarian cysadenocarcinoma, mesothelioma, lung squamous cell carcinoma, lung adenocarcinoma, liver hepatocellular carcinoma, kidney papillary cell carcinoma, kidney clear cell carcinoma, kidney chromophobe, head and neck squamous cell carcinoma, glioblastoma multiforme, diffuse large B-cell lymphoma, colon adenocarcinoma, cholangiocarcinoma, cervical and endocervical cancer, breast invasive carcinoma,
  • FIGS. 24A-C show immunohistochemistry of human melanoma biopsies from 3 patients. The results demonstrate abundant KLRG1+ cells (stained black) infiltrating tumor. Isotype controls were used as negative controls (not shown).
  • FIG. 24D shows absence of KLRG1+ cells in normal skin. The presence of KLRG1+ cells in tumor tissue render melanoma a particularly attractive target for therapies according to the present invention.
  • FIG. 25 shows immunohistochemistry of human renal cell carcinoma biopsies from 4 patients. The results demonstrate abundant KLRG1+ cells (stained black) infiltrating tumor. Isotype controls were used as negative controls (not shown). The presence of KLRG1+ cells in tumor tissue render renal cell carcinoma a particularly attractive target for therapies according to the present invention.
  • FIG. 26 shows immunohistochemistry of human non-small cell lung cancer biopsies from 4 patients. Abundant KLRG1+ cells (stained black) infiltrating tumor were observed. Isotype controls were used as negative controls (not shown). The presence of KLRG1+ cells in tumor tissue render non-small cell lung cancer a particularly attractive target for therapies according to the present invention.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
US16/327,576 2016-09-16 2017-09-15 Klrg1 depletion therapy Abandoned US20190194333A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US16/327,576 US20190194333A1 (en) 2016-09-16 2017-09-15 Klrg1 depletion therapy

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662395551P 2016-09-16 2016-09-16
US16/327,576 US20190194333A1 (en) 2016-09-16 2017-09-15 Klrg1 depletion therapy
PCT/US2017/051776 WO2018053264A2 (fr) 2016-09-16 2017-09-15 Thérapie par épuisement de klrg1

Publications (1)

Publication Number Publication Date
US20190194333A1 true US20190194333A1 (en) 2019-06-27

Family

ID=61619243

Family Applications (1)

Application Number Title Priority Date Filing Date
US16/327,576 Abandoned US20190194333A1 (en) 2016-09-16 2017-09-15 Klrg1 depletion therapy

Country Status (7)

Country Link
US (1) US20190194333A1 (fr)
EP (1) EP3512553A4 (fr)
JP (1) JP2019529416A (fr)
CN (1) CN110300598A (fr)
AU (1) AU2017326003A1 (fr)
CA (1) CA3036835A1 (fr)
WO (1) WO2018053264A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024091919A3 (fr) * 2022-10-25 2024-06-20 The Brigham And Women's Hospital, Inc. Agents de liaison à klrb1 et leurs méthodes d'utilisation

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210002373A1 (en) * 2018-03-01 2021-01-07 Nextcure, Inc. KLRG1 Binding Compositions and Methods of Use Thereof
KR20210060477A (ko) * 2018-09-17 2021-05-26 압큐로, 인크. 항-klrg1 항체
US11180561B2 (en) 2019-04-09 2021-11-23 Abcuro, Inc. Killer cell lectin-like receptor subfamily G member 1 (KLRG1) depleting antibodies
WO2022056289A1 (fr) * 2020-09-11 2022-03-17 National Jewish Health Procédés et compositions pour le traitement de maladies ou d'affections respiratoires liées à des cellules lymphoïdes innées
CN113058029A (zh) * 2021-03-18 2021-07-02 西安交通大学 胶原凝集素-11在制备防治泌尿系统感染的药物中的应用
AU2022320627A1 (en) 2021-07-26 2024-02-08 Abcuro, Inc. Killer cell lectin-like receptor subfamily g member 1 (klrg1) depleting antibodies

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE199392T1 (de) * 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
US8637084B2 (en) * 2009-07-14 2014-01-28 Asahi Kasei Medical Co., Ltd. Treatment method for epithelial cancerous organism
JP2012025694A (ja) * 2010-07-23 2012-02-09 Asahi Kasei Kuraray Medical Co Ltd 癌治療剤
JP6611709B2 (ja) * 2013-06-25 2019-11-27 バクシネックス インコーポレーティッド 腫瘍成長および転移を阻害するための免疫調節療法との組み合わせでのセマフォリン−４ｄ阻害分子の使用
JP6721145B2 (ja) * 2014-07-25 2020-07-08 国立研究開発法人理化学研究所 メモリーインバリアントｎｋｔ細胞マーカー
WO2017210523A1 (fr) * 2016-06-03 2017-12-07 The Brigham And Women's Hospital Traitement de signalisation par klrg1

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024091919A3 (fr) * 2022-10-25 2024-06-20 The Brigham And Women's Hospital, Inc. Agents de liaison à klrb1 et leurs méthodes d'utilisation

Also Published As

Publication number Publication date
EP3512553A2 (fr) 2019-07-24
JP2019529416A (ja) 2019-10-17
AU2017326003A1 (en) 2019-04-11
CN110300598A (zh) 2019-10-01
EP3512553A4 (fr) 2021-01-06
WO2018053264A2 (fr) 2018-03-22
CA3036835A1 (fr) 2018-03-22
WO2018053264A3 (fr) 2019-05-23

Similar Documents

Publication Publication Date Title
JP7021153B2 (ja) 腫瘍成長および転移を阻害するための免疫調節療法との組み合わせでのセマフォリン－４ｄ阻害分子の使用
US10688180B2 (en) Combination of anti-KIR and anti-CTLA-4 antibodies to treat cancer
US20190194333A1 (en) Klrg1 depletion therapy
JP7163260B2 (ja) 腫瘍を処置するための抗ｌａｇ－３抗体と抗ｐｄ－１抗体との組合せ
US20180099045A1 (en) Combination of anti-kir antibodies and anti-pd-1 antibodies to treat cancer
US20230096030A1 (en) Bispecific antibodies against cd9 and cd7
JP2022163078A (ja) 移植片対宿主病予防の方法
EP4103611B1 (fr) Anticorps bispecifiques se liant a hvem et a cd9
US20240092934A1 (en) Assessment of ceacam1 expression on tumor infiltrating lymphocytes
US20230151109A1 (en) Bispecific antibodies against cd9
US20230151108A1 (en) Bispecific antibodies against cd9 and cd137
EA041816B1 (ru) Способ профилактики болезни "трансплантат против хозяина"

Legal Events

Date Code Title Description
STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION